| Literature DB >> 23056922 |
L Kimura1, C B Angeli, M T B M Auricchio, G R Fernandes, A C Pereira, J P Vicente, T V Pereira, R C Mingroni-Netto.
Abstract
Background. It has been widely suggested that analyses considering multilocus effects would be crucial to characterize the relationship between gene variability and essential hypertension (EH). Objective. To test for the presence of multilocus effects between/among seven polymorphisms (six genes) on blood pressure-related traits in African-derived semi-isolated Brazilian populations (quilombos). Methods. Analyses were carried out using a family-based design in a sample of 652 participants (97 families). Seven variants were investigated: ACE (rs1799752), AGT (rs669), ADD2 (rs3755351), NOS3 (rs1799983), GNB3 (rs5441 and rs5443), and GRK4 (rs1801058). Sensitivity analyses were further performed under a case-control design with unrelated participants only. Results. None of the investigated variants were associated individually with both systolic and diastolic BP levels (SBP and DBP, respectively) or EH (as a binary outcome). Multifactor dimensionality reduction-based techniques revealed a marginal association of the combined effect of both GNB3 variants on DBP levels in a family-based design (P = 0.040), whereas a putative NOS3-GRK4 interaction also in relation to DBP levels was observed in the case-control design only (P = 0.004). Conclusion. Our results provide limited support for the hypothesis of multilocus effects between/among the studied variants on blood pressure in quilombos. Further larger studies are needed to validate our findings.Entities:
Year: 2012 PMID: 23056922 PMCID: PMC3463917 DOI: 10.1155/2012/859219
Source DB: PubMed Journal: Int J Hypertens Impact factor: 2.420
Descriptive statistics of 652 individuals from 12 quilombo populations regarding to studied phenotypes.
|
| |
|---|---|
| Age (years) | 43.5 (17–91) |
| Male (%) | 45.6% |
| SBP (mmHg) | 131.8 ± 25.6 |
| DBP (mmHg) | 82 ± 13.7 |
| Hypertension* | 41.6% |
| BMI (Kg/m2) | 24.7 ± 4.48 |
| BMI > 25 Kg/m2 | 41.9% |
*Hypertension was defined as a SBP ≥ 140 mmHg and/or a DBP ≥ 90 mmHg or use of antihypertensive medications.
FBAT analysis for blood pressure-related traits in quilombos.
| Gene | Variant | rs |
| Phenotypes | |||
|---|---|---|---|---|---|---|---|
| EH | SBP | DBP | |||||
|
| I/D | rs1799752 | 0.50 | NIF | 97 | 93 | 95 |
|
| 0.774 | 0.155 | 0.123 | ||||
|
| Glu298Asp | rs1799983 | 0.16 | NIF | 63 | 63 | 61 |
|
| 0.101 | 0.050 | 0.079 | ||||
|
| C825T | rs5443 | 0.58 | NIF | 86 | 84 | 82 |
|
| 0.793 | 0.417 | 0.342 | ||||
|
| G-350A | rs5441 | 0.68 | NIF | 79 | 76 | 76 |
|
| 0.063 | 0.672 | 0.565 | ||||
|
| M235T | rs699 | 0.27 | NIF | 96 | 92 | 94 |
|
| 0.608 | 0.293 | 0.579 | ||||
|
| c.-154+20128C>A | rs3755351 | 0.34 | NIF | 97 | 93 | 95 |
|
| 0.196 | 0.209 | 0.137 | ||||
|
| A486V | rs1801058 | 0.24 | NIF | 70 | 69 | 68 |
|
| 0.096 | 0.229 | 0.230 | ||||
NIF: number of informative families. F: allele frequency for the risk allele. EH: essential hypertension. SBP: systolic blood pressure (mmHG). DBP: diastolic blood pressure (mmHg). All analyses were adjusted for covariates (age, gender, and BMI when appropriate). Similar results were obtained for other FBAT approaches (e.g. prevalence adjusted, mean centered, or minimal variance approaches) (data now shown). All results refer to analyses performed under assumption of an additive model of action. Qualitatively analogous results were observed for other genetic models (e.g., dominant and recessive) (data not shown).
Best two-locus models from FAM-MDR analyses.
| Phenotype | Model |
|
|
|---|---|---|---|
| SBP |
| 8.203 | 0.533 |
|
| 6.318 | 0.819 | |
|
| 6.043 | 0.837 | |
|
| 4.172 | 0.981 | |
|
| 3.864 | 0.984 | |
|
| 3.146 | 0.997 | |
|
| |||
| DBP |
| 14.064 | 0.040 |
|
| 8.500 | 0.460 | |
|
| 8.014 | 0.512 | |
|
| 7.970 | 0.512 | |
|
| 6.763 | 0.681 | |
|
| 6.364 | 0.732 | |
SBP: systolic blood pressure. DBP: diastolic blood pressure.
Clinical characteristics of the unrelated quilombo sample.
| Normotensives ( | Hypertensives ( |
| |
|---|---|---|---|
| Gender | |||
| Men | 98 (47.57) | 79 (44.38) | 0.540 |
| Women | 108 (52.43) | 99 (55.62) | |
| Age (years) | 32 (24.5–44.7) | 55.7 (42.4–67.4) | <0.001 |
| Adjusted SBP (mmHg)∗ | 115.54 ± 12.29 | 155.85 ± 21.39 | <0.001 |
| Adjusted DBP (mmHg)∗ | 74.79 ± 7.22 | 94.84 ± 13.60 | <0.001 |
| BMI (Kg/m2) | 23.95 ± 3.89 | 25.79 ± 4.40 | <0.001 |
∗Adjusted for the antihypertensive use according the proposition by Tobin et al. [11].
Genotype frequencies for the seven studied polymorphisms in normotensive and hypertensive quilombo subjects.
| Gene/Status | Genotype, |
|
|
| ||
|---|---|---|---|---|---|---|
|
| I/I | I/D | D/D | |||
| Hypertensive | 39 (21.91) | 92 (51.69) | 47 (26.40) | 0.474 | 0.518 | 0.227 |
| Normotensive | 54 (26.21) | 92 (44.66) | 60 (29.13) | |||
|
| Glu/Glu | Glu/Asp | Asp/Asp | |||
| Hypertensive | 127 (71.35) | 47 (26.40) | 4 (2.25) | 0.842 | 0.150 | 0.922 |
| Normotensive | 151 (73.30) | 50 (24.27) | 5 (2.43) | |||
|
| C/C | C/T | T/T | |||
| Hypertensive | 42 (23.60) | 74 (41.57) | 62 (34.83) | 0.999 | 0.592 | 0.054 |
| Normotensive | 22 (10.68) | 111 (53.88) | 73 (35.44) | |||
|
| G/G | A/G | A/A | |||
| Hypertensive | 93 (52.25) | 60 (33.71) | 25 (14.04) | 0.028 | 0.297 | 0.595 |
| Normotensive | 106 (51.46) | 82 (39.81) | 18 (8.74) | |||
|
| Thr/Thr | Thr/Met | Met/Met | |||
| Hypertensive | 91 (51.12) | 73 (41.01) | 14 (7.87) | 0.425 | 0.259 | 0.482 |
| Normotensive | 123 (59.71) | 68 (33.01) | 15 (7.28) | |||
|
| A/A | A/C | C/C | |||
| Hypertensive | 27 (15.17) | 94 (45.63) | 83 (46.63) | 0.256 | 0.661 | 0.565 |
| Normotensive | 22 (10.68) | 68 (38.20) | 90 (43.69) | |||
|
| Ala/Ala | Ala/Val | Val/Val | |||
| Hypertensive | 98 (55.06) | 72 (40.45) | 8 (4.49) | 0.893 | 0.253 | 0.586 |
| Normotensive | 117 (56.80) | 72 (34.95) | 17 (8.25) | |||
HWE: Hardy-Weinberg equilibrium; F: frequency of the risk allele; MAX3: max-statistic; MAX3-based results are adjusted for age, gender, and BMI.
Analysis of haplotypic effects (G-350A/C825T) on blood pressure-related phenotypes.
| Trait |
| Haplotypes | Haplotypic effects | LD measures | LR test | ||||
|---|---|---|---|---|---|---|---|---|---|
| G(-350A) | C825T | OR (95% CI) |
|
|
|
|
| ||
| Hypertension | 384 | G | C | reference | — | 0.40 | 0.10 | 5.29 (3) | 0.152 |
| G | T | 0.586 (0.358–0.958) | 0.033 | ||||||
| A | C | 0.591 (0.336–1.040) | 0.068 | ||||||
| A | T | 0.865 (0.451– 1.659) | 0.661 | ||||||
|
| |||||||||
| Δ (95% CI) |
| ||||||||
|
| |||||||||
| SBP (mmHg) | 384 | G | C | reference | — | 0.40 | 0.10 | 7.04 (3) | 0.071 |
| G | T | −2.208 (−6.734–2.318) | 0.339 | ||||||
| A | C | −0.482 (−5.95–4.986) | 0.862 | ||||||
| A | T | −1.361 (−7.39–4.67) | 0.658 | ||||||
|
| |||||||||
| Δ (95% CI) |
| ||||||||
|
| |||||||||
| DBP (mmHg) | 384 | G | C | reference | — | 0.40 | 0.10 | 2.82 (3) | 0.420 |
| G | T | −1.247 (−3.878–1.383) | 0.352 | ||||||
| A | C | −2.328 (−5.447–0.792) | 0.143 | ||||||
| A | T | −1.996 (−5.596–1.605) | 0.277 | ||||||
N: sample size. OR: odds ratio. EH: essential hypertension. LD: linkage disequilibrium. LR: likelihood ratio. df: degrees of freedom. Δ: expected linear increment in the trait per additional copy of the haplotype (in mmHg). All results refer to the additive model of analysis and are adjusted for age, gender, and BMI. Analyses were also performed under both dominant and recessive models of action, yielding qualitatively analogous results (data not shown). The overall proportion of haplotypes G-350A/C825T in the studied population was 0.197, 0.499, 0.196, and 0.108 for haplotypes GC, GT, AC, and AT, respectively. For the hypertension status, haplotypic frequencies for hypertensive/normotensive participants were as follows: GC: 0.248/0.186, GT: 0.443/0.523, AC: 0.195/0.190 and AT: 0.114/0.10.
Best predictive models from GMDR analyses.
| Model | Test accuracy | CVC |
|
|---|---|---|---|
| Hypertension | |||
|
| 0.4884 | 4 | 0.5324 |
|
| 0.5569 | 4 | 0.0792 |
|
| 0.5850 | 3 | 0.0222 |
|
| |||
| Systolic blood pressure | |||
|
| 0.5220 | 5 | 0.2644 |
|
| 0.5752 | 5 | 0.0444 |
|
| 0.5282 | 4 | 0.2440 |
|
| |||
| Diastolic blood pressure | |||
|
| 0.6031 | 9 | 0.0044 |
|
| 0.5677 | 3 | 0.0724 |
|
| 0.6347 | 6 | 0.0014 |
CVC: cross-validation consistency.